Grace Therapeutics VP of Clinical Ops departing, will consult at $250/hr for NDA work

Grace Therapeutics, Inc.

Carrie D'Andrea, VP of Clinical Operations, to cease employment effective June 5, 2026.
She entered a 12-month consulting agreement at $250/hour for clinical development and NDA-related services.
Stock option awards will continue to vest during the consulting term and remain exercisable for 90 days after termination.
Severance benefits per November 2025 letter agreement, conditioned on release of claims and non-compete/non-solicitation covenants.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Carrie D'Andrea

Vice President of Clinical Operations

GRCE · Grace Therapeutics, Inc.

Effective: 2026-06-05
Filed: June 5, 2026, 4:09 PM ET

Carrie D’Andrea will cease serving as Vice President of Clinical Operations of the Company and will no longer be employed by the Company effective June 5, 2026

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Carrie D'Andrea departed as Vice President of Clinical Operations at Grace Therapeutics, Inc..

Action: ceased serving as Vice President of Clinical Operations
Role: Vice President of Clinical Operations

Exact text from the filing

Carrie D’Andrea will cease serving as Vice President of Clinical Operations of the Company and will no longer be employed by the Company effective June 5, 2026

View on SEC.gov

Grace Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-26-024269

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.